

Carmel Mary Hawley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3062130/publications.pdf>

Version: 2024-02-01

262
papers

11,592
citations

19657

61
h-index

43889

91
g-index

267
all docs

267
docs citations

267
times ranked

9863
citing authors

#	ARTICLE	IF	CITATIONS
1	Sclerosing peritonitis: the experience in Australia. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 154-159.	0.7	300
2	Non-melanoma skin cancer risk in the Queensland renal transplant population. <i>British Journal of Dermatology</i> , 2002, 147, 950-956.	1.5	263
3	A Randomized Trial of Dietary Sodium Restriction in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 2096-2103.	6.1	253
4	Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. <i>American Journal of Kidney Diseases</i> , 2017, 70, 464-475.	1.9	218
5	The effect of obesity on renal transplant outcomes. <i>Transplantation</i> , 2002, 74, 675-681.	1.0	217
6	Effects of Early and Late Intervention with Epoetin $\hat{\pm}$ on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4). <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 148-156.	6.1	206
7	Recent Peritonitis Associates with Mortality among Patients Treated with Peritoneal Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1398-1405.	6.1	198
8	Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 406-413.	0.7	191
9	Home Hemodialysis and Mortality Risk in Australian and New Zealand Populations. <i>American Journal of Kidney Diseases</i> , 2011, 58, 782-793.	1.9	168
10	Patients' Experiences and Perspectives of Living With CKD. <i>American Journal of Kidney Diseases</i> , 2009, 53, 689-700.	1.9	162
11	Incremental Value of Strain Rate Analysis as an Adjunct to Wall-Motion Scoring for Assessment of Myocardial Viability by Dobutamine Echocardiography. <i>Circulation</i> , 2005, 112, 3892-3900.	1.6	159
12	Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. <i>Kidney International</i> , 2010, 77, 904-912.	5.2	154
13	A randomized controlled trial of topical exit site mupirocin application in patients with tunneled, cuffed haemodialysis catheters. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1802-1807.	0.7	148
14	Effects of Beta-Adrenergic Antagonists in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1152-1161.	2.8	148
15	Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrologyâ€™Hemodialysis (SONG-HD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2017, 69, 97-107.	1.9	148
16	A COMPARISON OF THE EFFECTS OF DIALYSIS AND RENAL TRANSPLANTATION ON THE SURVIVAL OF OLDER UREMIC PATIENTS. <i>Transplantation</i> , 2000, 69, 794-799.	1.0	138
17	Protein-bound Uremic Toxins, Inflammation and Oxidative Stress: A Cross-sectional Study in Stage 3â€™4 Chronic Kidney Disease. <i>Archives of Medical Research</i> , 2014, 45, 309-317.	3.3	137
18	Randomized, Controlled Trial of Topical Exit-Site Application of Honey (Medihoney) versus Mupirocin for the Prevention of Catheter-Associated Infections in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1456-1462.	6.1	135

#	ARTICLE	IF	CITATIONS
19	Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. <i>Kidney International</i> , 2009, 76, 622-628.	5.2	134
20	Patients' priorities for health research: focus group study of patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3206-3214.	0.7	124
21	Incidence and prediction of nonmelanoma skin cancer post-renal transplantation: A prospective study in Queensland, Australia. <i>American Journal of Kidney Diseases</i> , 2003, 41, 676-683.	1.9	122
22	Endovascular Proximal Forearm Arteriovenous Fistula for Hemodialysis Access: Results of the Prospective, Multicenter Novel Endovascular Access Trial (NEAT). <i>American Journal of Kidney Diseases</i> , 2017, 70, 486-497.	1.9	115
23	Associations of Dialysis Modality and Infectious Mortality in Incident Dialysis Patients in Australia and New Zealand. <i>American Journal of Kidney Diseases</i> , 2009, 53, 290-297.	1.9	112
24	Is C-Reactive Protein a Useful Predictor of Outcome in Peritoneal Dialysis Patients?. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 814-821.	6.1	111
25	Obesity is Associated with Worsening Cardiovascular Risk Factor Profiles and Proteinuria Progression in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 2710-2718.	4.7	107
26	Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 397-406.	1.2	105
27	Effect of Hemodiafiltration or Hemofiltration Compared With Hemodialysis on Mortality and Cardiovascular Disease in Chronic Kidney Failure: A Systematic Review and Meta-analysis of Randomized Trials. <i>American Journal of Kidney Diseases</i> , 2014, 63, 968-978.	1.9	105
28	Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. <i>Nephrology</i> , 2007, 12, 391-398.	1.6	102
29	Left Ventricular Global Longitudinal Strain (GLS) Is a Superior Predictor of All-Cause and Cardiovascular Mortality When Compared to Ejection Fraction in Advanced Chronic Kidney Disease. <i>PLoS ONE</i> , 2015, 10, e0127044.	2.5	101
30	Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 271-280.	2.4	97
31	Multicenter Registry Analysis of Center Characteristics Associated with Technique Failure in Patients on Incident Peritoneal Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1090-1099.	4.5	94
32	Buttonhole Cannulation and Clinical Outcomes in a Home Hemodialysis Cohort and Systematic Review. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 110-119.	4.5	93
33	<i>Pseudomonas</i> Peritonitis in Australia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 957-964.	4.5	92
34	Sclerosing Peritonitis: Identification of Diagnostic, Clinical, and Radiological Features. <i>American Journal of Kidney Diseases</i> , 1994, 24, 819-825.	1.9	91
35	Association of Dialysis Modality and Cardiovascular Mortality in Incident Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1620-1628.	4.5	85
36	Culture-Negative Peritonitis in Peritoneal Dialysis Patients in Australia: Predictors, Treatment, and Outcomes in 435 Cases. <i>American Journal of Kidney Diseases</i> , 2010, 55, 690-697.	1.9	85

#	ARTICLE	IF	CITATIONS
37	Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. <i>American Journal of Kidney Diseases</i> , 2018, 72, 188-197.	1.9	85
38	Staphylococcus Aureus Peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment, and Outcomes in 503 Cases. <i>Peritoneal Dialysis International</i> , 2010, 30, 311-319.	2.3	84
39	Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1973-1979.	0.7	84
40	Polymicrobial Peritonitis in Peritoneal Dialysis Patients in Australia: Predictors, Treatment, and Outcomes. <i>American Journal of Kidney Diseases</i> , 2010, 55, 121-131.	1.9	80
41	Impact of obesity on renal transplant outcomes. <i>Nephrology</i> , 2005, 10, 405-413.	1.6	78
42	Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis. <i>JAMA Internal Medicine</i> , 2017, 177, 184.	5.1	77
43	Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 23-30.	9.1	76
44	The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 591-598.	1.9	74
45	Research Priorities in CKD: Report of a National Workshop Conducted in Australia. <i>American Journal of Kidney Diseases</i> , 2015, 66, 212-222.	1.9	73
46	Early and Late Patient Outcomes in Urgent-Start Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2017, 37, 414-419.	2.3	73
47	A Randomized Controlled Trial of Coiled Versus Straight Swan-Neck Tenckhoff Catheters in Peritoneal Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2006, 48, 812-821.	1.9	71
48	Kidneys from patients with small renal tumours: a novel source of kidneys for transplantation. <i>BJU International</i> , 2008, 102, 188-193.	2.5	71
49	Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1272-1278.	0.7	70
50	Establishing a Core Outcome Measure for Fatigue in Patients on Hemodialysis: A Standardized Outcomes in Nephrologyâ€™Hemodialysis (SONG-HD) Consensus Workshop Report. <i>American Journal of Kidney Diseases</i> , 2018, 72, 104-112.	1.9	69
51	Automated and continuous ambulatory peritoneal dialysis have similar outcomes. <i>Kidney International</i> , 2008, 73, 480-488.	5.2	68
52	The impact of automated eGFR reporting and education on nephrology service referrals. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3845-3850.	0.7	68
53	Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. <i>American Heart Journal</i> , 2006, 151, 745-753.	2.7	67
54	Standardised outcomes in nephrology â€™ Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. <i>Trials</i> , 2015, 16, 364.	1.6	67

#	ARTICLE	IF	CITATIONS
55	Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. <i>American Journal of Kidney Diseases</i> , 2018, 71, 814-821.	1.9	66
56	Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 146-152.	0.7	64
57	Intradermal Versus Intramuscular Hepatitis B Vaccination in Hemodialysis Patients: A Prospective Open-Label Randomized Controlled Trial in Nonresponders to Primary Vaccination. <i>American Journal of Kidney Diseases</i> , 2009, 54, 95-103.	1.9	63
58	Relapsing and Recurrent Peritoneal Dialysis-Associated Peritonitis: A Multicenter Registry Study. <i>American Journal of Kidney Diseases</i> , 2011, 58, 429-436.	1.9	63
59	Predictors, treatment, and outcomes of non-Pseudomonas Gram-negative peritonitis. <i>Kidney International</i> , 2010, 78, 408-414.	5.2	62
60	How Australian nephrologists view home dialysis: Results of a national survey. <i>Nephrology</i> , 2011, 16, 446-452.	1.6	62
61	A Trial of Extending Hemodialysis Hours and Quality of Life. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1898-1911.	6.1	62
62	Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure for Hemodialysis Vascular Access. <i>American Journal of Kidney Diseases</i> , 2018, 71, 690-700.	1.9	62
63	The impact of extended-hours home hemodialysis and buttonhole cannulation technique on hospitalization rates for septic events related to dialysis access. <i>Hemodialysis International</i> , 2010, 14, 451-463.	0.9	61
64	Coagulase-negative staphylococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 936 cases. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3386-3392.	0.7	60
65	Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. <i>Kidney International</i> , 2013, 83, 503-510.	5.2	59
66	Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access Outcomes in REnal Disease (FAVOURED) study. <i>BMC Nephrology</i> , 2009, 10, 1.	1.8	58
67	The association between left ventricular global longitudinal strain, renal impairment and all-cause mortality. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1218-1225.	0.7	56
68	Recovery of gastrointestinal function after renal transplantation in a patient with sclerosing peritonitis secondary to continuous ambulatory peritoneal dialysis. <i>American Journal of Kidney Diseases</i> , 1995, 26, 658-661.	1.9	55
69	Predicting Risk of Nonmelanoma Skin Cancer and Premalignant Skin Lesions in Renal Transplant Recipients. <i>Transplantation</i> , 2009, 87, 1667-1671.	1.0	54
70	A randomised controlled trial of Heparin versus Ethanol Lock Therapy for the prevention of Catheter Associated infection in Haemodialysis patients - the HEALTHY-CATH trial. <i>BMC Nephrology</i> , 2012, 13, 146.	1.8	54
71	Center-Specific Factors Associated with Peritonitis Risk - A Multi-Center Registry Analysis. <i>Peritoneal Dialysis International</i> , 2016, 36, 509-518.	2.3	54
72	Does Uric Acid Have a Pathogenetic Role in Graft Dysfunction and Hypertension in Renal Transplant Recipients?. <i>Transplantation</i> , 2005, 80, 1565-1571.	1.0	53

#	ARTICLE	IF	CITATIONS
73	Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases. <i>BMC Nephrology</i> , 2009, 10, 19.	1.8	52
74	Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home. <i>American Journal of Kidney Diseases</i> , 2013, 61, 247-253.	1.9	52
75	The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 554-563.	1.9	51
76	An Incident Cohort Study Comparing Survival on Home Hemodialysis and Peritoneal Dialysis (Australia) <i>Tj ETQq0 0 0 rgBT /Overlock 10 T</i> <i>Nephrology: CJASN</i> , 2015, 10, 1397-1407.	4.5	50
77	Polymorphisms of the renin-angiotensin system in patients with multifocal renal arterial fibromuscular dysplasia. <i>Journal of Human Hypertension</i> , 2001, 15, 185-190.	2.2	48
78	Should an Oral Glucose Tolerance Test Be Performed Routinely in All Renal Transplant Recipients?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 100-108.	4.5	48
79	Daily Variation in Death in Patients Treated by Long-term Dialysis: Comparison of In-Center Hemodialysis to Peritoneal and Home Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2013, 61, 96-103.	1.9	48
80	<i>Corynebacterium</i> peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3834-3839.	0.7	46
81	Challenges of conducting a trial of uric-acid-lowering therapy in CKD. <i>Nature Reviews Nephrology</i> , 2011, 7, 295-300.	9.6	46
82	Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. <i>BMC Nephrology</i> , 2014, 15, 8.	1.8	46
83	Polymorphisms in glutathione S-transferases and non-melanoma skin cancer risk in Australian renal transplant recipients. <i>Carcinogenesis</i> , 2004, 26, 185-191.	2.8	45
84	A randomized trial of sodium-restriction on kidney function, fluid volume and adipokines in CKD patients. <i>BMC Nephrology</i> , 2014, 15, 57.	1.8	44
85	Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. <i>Kidney International</i> , 2016, 89, 1337-1345.	5.2	44
86	Chronic Kidney Disease and Pulse Wave Velocity: A Narrative Review. <i>International Journal of Hypertension</i> , 2019, 2019, 1-11.	1.3	44
87	The Outcomes of Patients with ESRD and ANCA-Associated Vasculitis in Australia and New Zealand. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 773-780.	4.5	43
88	Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?. <i>BMC Nephrology</i> , 2011, 12, 20.	1.8	42
89	Changes in serum prolactin, sex hormones and thyroid function with alternate nightly nocturnal home haemodialysis. <i>Nephrology</i> , 2012, 17, 42-47.	1.6	42
90	Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. <i>Nephrology</i> , 2012, 17, 433-444.	1.6	42

#	ARTICLE	IF	CITATIONS
91	Intensive Hemodialysis and Mortality Risk in Australian and New Zealand Populations. American Journal of Kidney Diseases, 2016, 67, 617-628.	1.9	42
92	Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. Nephrology Dialysis Transplantation, 2006, 21, 776-783.	0.7	41
93	Temporal Changes in Mortality Risk by Dialysis Modality in the Australian and New Zealand Dialysis Population. American Journal of Kidney Diseases, 2015, 66, 489-498.	1.9	41
94	Prevalence of Skin Cancer and Related Skin Tumors in High-Risk Kidney and Liver Transplant Recipients in Queensland, Australia. Journal of Investigative Dermatology, 2016, 136, 1382-1386.	0.7	41
95	Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review. American Journal of Kidney Diseases, 2018, 71, 382-391.	1.9	41
96	ADVANCED DONOR-ORIGIN MELANOMA IN A RENAL TRANSPLANT RECIPIENT. Transplantation, 1998, 66, 655-661.	1.0	41
97	The effect of oral iron administration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. Transplantation, 2004, 77, 206-209.	1.0	40
98	End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases. Nephrology Dialysis Transplantation, 2014, 29, 2277-2286.	0.7	40
99	Focus on peritoneal dialysis training: working to decrease peritonitis rates. Nephrology Dialysis Transplantation, 2016, 31, gfu403.	0.7	40
100	Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The <i>bal</i> ANZ Trial. Peritoneal Dialysis International, 2017, 37, 283-289.	2.3	40
101	Free Fatty Acids Are Associated with Obesity, Insulin Resistance, and Atherosclerosis in Renal Transplant Recipients. Transplantation, 2005, 80, 937-944.	1.0	39
102	Quality of life and alternate nightly nocturnal home hemodialysis. Hemodialysis International, 2010, 14, 29-38.	0.9	39
103	Frequency and severity of acute rejection in live- versus cadaveric-donor renal transplants. Transplantation, 2003, 76, 1452-1457.	1.0	38
104	Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. Nephrology Dialysis Transplantation, 2012, 27, 381-387.	0.7	38
105	Transitional cell carcinoma in renal transplant recipients: the influence of compound analgesics. British Journal of Urology, 1998, 81, 229-233.	0.1	37
106	Elevated white cell count at commencement of peritoneal dialysis predicts overall and cardiac mortality. Kidney International, 2005, 67, 738-743.	5.2	37
107	End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. Nephrology Dialysis Transplantation, 2013, 28, 455-461.	0.7	37
108	The Association between Body Mass Index and Mortality in Incident Dialysis Patients. PLoS ONE, 2014, 9, e114897.	2.5	37

#	ARTICLE	IF	CITATIONS
109	Cutaneous manifestations of cytomegalovirus disease in renal transplant recipients: a case series. <i>Transplant Infectious Disease</i> , 2008, 10, 209-213.	1.7	36
110	The β -Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 902-911.	1.9	36
111	Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis. <i>Nephrology</i> , 2007, 12, 224-233.	1.6	35
112	Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. <i>Transplant International</i> , 2012, 25, 1182-1193.	1.6	35
113	Management of Bone Disease, Calcium, Phosphate and Parathyroid Hormone. <i>Nephrology</i> , 2006, 11, S230-61.	1.6	34
114	Clinical Causes of Inflammation in Peritoneal Dialysis Patients. <i>International Journal of Nephrology</i> , 2014, 2014, 1-9.	1.3	34
115	Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1940-1947.	0.7	34
116	Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: An observational study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 1035-1042.	2.6	34
117	Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1425-1436.	0.7	34
118	Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. <i>Pathology</i> , 2002, 34, 263-266.	0.6	33
119	End-stage kidney disease due to scleroderma—outcomes in 127 consecutive ANZDATA registry cases. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3165-3171.	0.7	33
120	A Randomized Controlled Trial of Intravenous or Oral Iron for Posttransplant Anemia in Kidney Transplantation. <i>Transplantation</i> , 2012, 93, 822-826.	1.0	33
121	Association between causes of peritoneal dialysis technique failure and all-cause mortality. <i>Scientific Reports</i> , 2018, 8, 3980.	3.3	32
122	Recovery of renal function in end-stage renal failure—comparison between peritoneal dialysis and haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2825-2831.	0.7	31
123	Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2028-2036.	0.7	31
124	A Randomized Controlled Trial of Fludrocortisone for the Treatment of Hyperkalemia in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2006, 47, 809-814.	1.9	30
125	Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1845-1855.	4.5	30
126	Estimated donor glomerular filtration rate is the most important donor characteristic predicting graft function in recipients of kidneys from live donors. <i>Transplant International</i> , 2007, 20, 64-72.	1.6	29

#	ARTICLE	IF	CITATIONS
127	N-Terminal Pro-B-Type Natriuretic Peptide Variability in Stable Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 620-629.	4.5	29
128	A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial. <i>American Journal of Kidney Diseases</i> , 2015, 65, 49-57.	1.9	29
129	Role of cytokine gene polymorphisms in acute rejection and renal impairment after liver transplantation. <i>Liver Transplantation</i> , 2001, 7, 255-263.	2.4	28
130	Left ventricular global longitudinal strain is associated with cardiovascular risk factors and arterial stiffness in chronic kidney disease. <i>BMC Nephrology</i> , 2015, 16, 106.	1.8	28
131	Post-transplant hepatosplenic T-cell lymphoma successfully treated with hyperCVAD regimen. <i>American Journal of Hematology</i> , 2008, 83, 330-333.	4.1	27
132	The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study. <i>BMC Nephrology</i> , 2012, 13, 41.	1.8	27
133	Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 715-22.	2.3	27
134	Health data linkage research in Australia remains challenging. <i>Internal Medicine Journal</i> , 2019, 49, 539-544.	0.8	27
135	Association of Biocompatible Peritoneal Dialysis Solutions with Peritonitis Risk, Treatment, and Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1556-1563.	4.5	26
136	End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases. <i>American Journal of Nephrology</i> , 2015, 42, 177-184.	3.1	26
137	The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with Chronic Kidney Disease: a randomised controlled trial. <i>BMC Nephrology</i> , 2009, 10, 41.	1.8	25
138	Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3-4: A randomized controlled trial. <i>Nephrology</i> , 2013, 18, 26-35.	1.6	25
139	Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. <i>Internal Medicine Journal</i> , 2015, 45, 1054-1065.	0.8	25
140	Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. <i>BMC Nephrology</i> , 2017, 18, 281.	1.8	25
141	Prevention of access-related infection in dialysis. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 1185-1200.	4.4	24
142	A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4146-4153.	0.7	24
143	Renal services disaster planning: Lessons learnt from the 2011 Queensland floods and North Queensland cyclone experiences. <i>Nephrology</i> , 2013, 18, 41-46.	1.6	24
144	Multicentre registry data analysis comparing outcomes of culture-negative peritonitis and different subtypes of culture-positive peritonitis in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2020, 40, 47-56.	2.3	24

#	ARTICLE	IF	CITATIONS
145	Baseline Serum Interleukin-6 Predicts Cardiovascular Events in Incident Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2015, 35, 35-42.	2.3	23
146	A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients. <i>Clinical Transplantation</i> , 1999, 13, 520-525.	1.6	22
147	Australian consumer perspectives on dialysis: First national census. <i>Nephrology</i> , 2012, 17, 703-709.	1.6	22
148	Home Hemodialysis in Australia and New Zealand: How and Why it has been Successful. <i>Seminars in Dialysis</i> , 2011, 24, 658-663.	1.3	21
149	The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. <i>BMC Nephrology</i> , 2015, 16, 89.	1.8	21
150	Complications of home hemodialysis. <i>Hemodialysis International</i> , 2008, 12, S21-S25.	0.9	20
151	Uremic Toxin Development in Living Kidney Donors. <i>Transplantation</i> , 2014, 97, 548-554.	1.0	20
152	Outcomes of integrated home dialysis care: a multi-centre, multi-national registry study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1897-1904.	0.7	20
153	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. <i>The Cochrane Library</i> , 2017, 2, CD009966.	2.8	20
154	International quotidian dialysis registry: Annual report 2009. <i>Hemodialysis International</i> , 2009, 13, 240-249.	0.9	19
155	Repeated Peritoneal Dialysis-associated Peritonitis: A Multicenter Registry Study. <i>American Journal of Kidney Diseases</i> , 2012, 59, 84-91.	1.9	19
156	The Role of Monitoring Vancomycin Levels in Patients with Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2015, 35, 222-228.	2.3	19
157	Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. <i>Nephrology</i> , 2004, 9, 406-413.	1.6	18
158	Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes. <i>International Journal of Nephrology</i> , 2012, 2012, 1-9.	1.3	18
159	Outcomes of <i>Corynebacterium</i> Peritonitis: A Multicenter Registry Analysis. <i>Peritoneal Dialysis International</i> , 2017, 37, 619-626.	2.3	18
160	Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the Impact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study. <i>BMJ Open</i> , 2019, 9, e024382.	1.9	18
161	<i>Moraxella nonliquefaciens</i> Septic Arthritis in a Patient Undergoing Hemodialysis. <i>Clinical Infectious Diseases</i> , 1995, 21, 1039-1040.	5.8	17
162	Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. <i>BMC Nephrology</i> , 2008, 9, 8.	1.8	17

#	ARTICLE	IF	CITATIONS
163	Rationale and design of the HEALTHY-CATH trial: A randomised controlled trial of Heparin versus EthAnol Lock THERapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology, 2009, 10, 23.	1.8	17
164	The effect of lowering salt intake on ambulatory blood pressure to reduce cardiovascular risk in chronic kidney disease (LowSALT CKD study): protocol of a randomized trial. BMC Nephrology, 2012, 13, 137.	1.8	17
165	Effects of Climatic Region on Peritonitis Risk, Microbiology, Treatment, and Outcomes: A Multicenter Registry Study. Peritoneal Dialysis International, 2013, 33, 75-85.	2.3	17
166	Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network. Kidney International, 2014, 85, 23-30.	5.2	17
167	Sodium depletion decreases hepatic metabolism of vasoactive intestinal peptide in the rabbit.. Journal of Physiology, 1989, 418, 251-259.	2.9	16
168	Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. BMC Nephrology, 2009, 10, 29.	1.8	16
169	International quotidian dialysis registry: Annual report 2010. Hemodialysis International, 2011, 15, 15-22.	0.9	16
170	Evaluation of limited sampling strategies for total and free prednisolone in adult kidney transplant recipients. European Journal of Clinical Pharmacology, 2011, 67, 1243-1252.	1.9	16
171	Weekend Compared with Weekday Presentations of Peritoneal Dialysisâ€“Associated Peritonitis. Peritoneal Dialysis International, 2012, 32, 516-524.	2.3	16
172	A limited sampling strategy for the simultaneous estimation of tacrolimus, mycophenolic acid and unbound prednisolone exposure in adult kidney transplant recipients. Nephrology, 2012, 17, 294-299.	1.6	16
173	Socio-Economic Status and Peritonitis in Australian Non-Indigenous Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2015, 35, 450-459.	2.3	16
174	Predictors of Transfer to Home Hemodialysis after Peritoneal Dialysis Completion. Peritoneal Dialysis International, 2016, 36, 547-554.	2.3	16
175	Comparison of Freeliteâ„¢ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1045-52.	2.3	16
176	Generalized, pruritic, ulcerating maculopapular rash necessitating cessation of sirolimus in a liver transplantation patient. Liver Transplantation, 2005, 11, 987-989.	2.4	15
177	Deceased donor renal transplantationâ€”does side matter?. Nephrology Dialysis Transplantation, 2006, 21, 2583-2588.	0.7	15
178	Is it time to revisit residual renal function in haemodialysis? (Review Article). Nephrology, 2007, 12, 209-217.	1.6	15
179	Cardiorespiratory Fitness Is Independently Associated with 25-Hydroxyvitamin D in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 512-518.	4.5	15
180	Cardiac surgical outcomes in abdominal solid organ (renal and hepatic) transplant recipients: a case-matched study. Interactive Cardiovascular and Thoracic Surgery, 2013, 16, 103-111.	1.1	15

#	ARTICLE	IF	CITATIONS
181	Association of anthropometric measures with kidney disease progression and mortality: a retrospective cohort study of pre-dialysis chronic kidney disease patients referred to a specialist renal service. <i>BMC Nephrology</i> , 2016, 17, 74.	1.8	15
182	The Role of Monitoring Gentamicin Levels in Patients with Gram-Negative Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2014, 34, 219-226.	2.3	14
183	The Effect of Exit-Site Antibacterial Honey versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the HoneyPot Trial. <i>Peritoneal Dialysis International</i> , 2015, 35, 712-721.	2.3	14
184	Association of Socio-Economic Position with Technique Failure and Mortality in Australian Non-Indigenous Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2017, 37, 397-406.	2.3	14
185	The SIESTA Trial: A Randomized Study Investigating the Efficacy, Safety, and Tolerability of Acupressure versus Sham Therapy for Improving Sleep Quality in Patients with End-Stage Kidney Disease on Hemodialysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-10.	1.2	14
186	NAV-KIDS2 trial: protocol for a multi-centre, staggered randomised controlled trial of a patient navigator intervention in children with chronic kidney disease. <i>BMC Nephrology</i> , 2019, 20, 134.	1.8	14
187	Effect of patient- and center-level characteristics on uptake of home dialysis in Australia and New Zealand: a multicenter registry analysis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1938-1949.	0.7	14
188	Severe hypokalaemia secondary to dicloxacillin. <i>Internal Medicine Journal</i> , 2002, 32, 357-358.	0.8	13
189	Alternate Night Nocturnal Hemodialysis: The Australian Experience. <i>Seminars in Dialysis</i> , 2011, 24, 664-667.	1.3	13
190	Treatment outcomes for ischemic heart disease in dialysis-dependent patients. <i>Asian Cardiovascular and Thoracic Annals</i> , 2012, 20, 281-291.	0.5	13
191	Multimodality vascular imaging in CKD: divergence of risk between measured parameters. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1004-1012.	0.7	13
192	Challenges in Blood Pressure Measurement in Patients Treated With Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2012, 60, 463-472.	1.9	13
193	Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1774-1779.	0.7	13
194	Association between left ventricular global longitudinal strain, health-related quality of life and functional capacity in chronic kidney disease patients with preserved ejection fraction. <i>Nephrology</i> , 2016, 21, 108-115.	1.6	12
195	Outcomes of <i>Acinetobacter</i> Peritonitis in Peritoneal Dialysis Patients: A Multicenter Registry Analysis. <i>Peritoneal Dialysis International</i> , 2018, 38, 257-265.	2.3	12
196	Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2178-2185.	0.7	11
197	Intravenous versus oral iron supplementation for correction of post-transplant anaemia in renal transplant patients. <i>BMC Nephrology</i> , 2009, 10, 14.	1.8	11
198	Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD?. <i>Nephrology</i> , 2011, 16, 144-153.	1.6	11

#	ARTICLE	IF	CITATIONS
199	Predictors of Vitamin D Status in Predialysis Chronic Kidney Disease Patients: A Cross-sectional Analysis in a High Ultraviolet Climate. , 2012, 22, 400-408.		11
200	Is Alpha-B Crystallin an Independent Marker for Prognosis in Lung Cancer?. Heart Lung and Circulation, 2013, 22, 759-766.	0.4	11
201	Association between serum hepcidin and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Nephrology, 2017, 22, 548-554.	1.6	11
202	Parathyroid hormone targets in chronic kidney disease and managing severe hyperparathyroidism. Nephrology, 2017, 22, 47-50.	1.6	11
203	Hemodynamic properties of bucindolol, a beta-adrenoreceptor blocking drug with vasodilator activity. American Journal of Cardiology, 1986, 57, 678-681.	1.6	10
204	Life-threatening adenovirus infection in a kidney transplant recipient. CKJ: Clinical Kidney Journal, 2009, 2, 250-253.	2.9	10
205	Cardiac and vascular structure and function parameters do not improve with alternate nightly home hemodialysis: An interventional cohort study. BMC Nephrology, 2011, 12, 51.	1.8	10
206	Baseline characteristics of the omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURED) study. Nephrology, 2016, 21, 217-228.	1.6	10
207	Impending challenges of the burden of end-stage kidney disease in Australia. Medical Journal of Australia, 2019, 211, 374.	1.7	10
208	Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1365-1375.	4.5	10
209	Durable and high rates of remission following chemotherapy in posttransplantation lymphoproliferative disorders after renal transplantation. Transplantation Proceedings, 2003, 35, 256-257.	0.6	9
210	Review Article: Is it time to embrace haemodiafiltration for centre-based haemodialysis? (Review) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 3	1.6	9
211	Change in live donor characteristics over the last 25 years: A single centre experience. Nephrology, 2008, 13, 646-650.	1.6	9
212	Rationale and design of the oral HEME iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 5	1.6	9
213	The HoneyPot Randomized Controlled Trial Statistical Analysis Plan. Peritoneal Dialysis International, 2013, 33, 426-435.	2.3	9
214	The Relationship between Body Mass Index and Organism-Specific Peritonitis. Peritoneal Dialysis International, 2018, 38, 206-214.	2.3	9
215	Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patients. CKJ: Clinical Kidney Journal, 2009, 2, 508-508.	2.9	8
216	Atypical HUS associated with severe, unexpected antibody-mediated rejection post kidney transplant. Nephrology, 2014, 19, 22-26.	1.6	8

#	ARTICLE	IF	CITATIONS
217	Association between Serum Alkaline Phosphatase and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial. Canadian Journal of Kidney Health and Disease, 2015, 2, 66.	1.1	8
218	The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Report, 2016, 21, 14-23.	4.5	8
219	Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study. Nephrology, 2016, 21, 387-396.	1.6	8
220	Higher Dialysate Matrix Metalloproteinase-2 Levels are Associated with Peritoneal Membrane Dysfunction. Peritoneal Dialysis International, 2016, 36, 16-25.	2.3	8
221	Response to article by Caponi et al. about serum free light chains. Clinical Chemistry and Laboratory Medicine, 2018, 57, e1-e2.	2.3	8
222	Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol. BMJ Open, 2019, 9, e023736.	1.9	8
223	Multiple Cerebral Aneurysms in an Adult With Autosomal Recessive Polycystic Kidney Disease. Kidney International Reports, 2021, 6, 219-223.	0.8	8
224	Baseline and time-averaged fluid removal affect technique survival in peritoneal dialysis in a non-linear fashion. Nephrology, 2007, 12, 218-223.	1.6	7
225	End-stage kidney disease due to haemolytic uraemic syndrome – outcomes in 241 consecutive ANZDATA registry cases. BMC Nephrology, 2012, 13, 164.	1.8	7
226	Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The BAL Anz Trial. Peritoneal Dialysis International, 2015, 35, 159-171.	2.3	7
227	Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial. Kidney and Blood Pressure Research, 2017, 42, 1033-1044.	2.0	7
228	Impact of Diabetes Mellitus on the Association of Vascular Disease Before Transplantation With Long-term Transplant and Patient Outcomes After Kidney Transplantation: A Population Cohort Study. American Journal of Kidney Diseases, 2018, 71, 102-111.	1.9	7
229	Onset of Dialysis Encephalopathy in Cyclosporine-Treated Renal Allograft Recipients. American Journal of Kidney Diseases, 1990, 15, 364-368.	1.9	6
230	Effect of Dialysis Modality on Survival of Hepatitis C-Infected ESRF Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2657-2661.	4.5	6
231	Interventions for erythropoietin-resistant anaemia in dialysis patients. The Cochrane Library, 2013, , CD006861.	2.8	6
232	Estimated GFR Reporting Influences Recommendations for Dialysis Initiation. Journal of the American Society of Nephrology: JASN, 2013, 24, 1737-1742.	6.1	6
233	The rationale and design of the Blocker to Lower Cardiovascular Diastolic Events (BLOCKADE) feasibility study. Nephrology, 2015, 20, 140-147.	1.6	6
234	Live donor study – implications of kidney donation on cardiovascular risk with a focus on lipid parameters including lipoprotein a. Nephrology, 2016, 21, 901-904.	1.6	6

#	ARTICLE	IF	CITATIONS
235	Association between Peritoneal Glucose Exposure and Peritonitis in Peritoneal Dialysis Patients: TheBalANZ Trial. <i>Peritoneal Dialysis International</i> , 2017, 37, 407-413.	2.3	6
236	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. <i>The Cochrane Library</i> , 0, , .	2.8	5
237	Sirolimus Increases T-Cell Abundance in the Sun Exposed Skin of Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2017, 3, e171.	1.6	5
238	Novel trial strategies to enhance the relevance, efficiency, effectiveness, and impact of nephrology research. <i>Kidney International</i> , 2020, 98, 572-578.	5.2	5
239	Kidney Transplant Outcomes in elderly Recipients: An Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry Study. <i>Transplantation Proceedings</i> , 2021, 53, 1915-1926.	0.6	5
240	Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. <i>Nephrology</i> , 2010, 15, 714-719.	1.6	4
241	Factors associated with acutely elevated serum creatinine following radical tumour nephrectomy: the Correlates of Kidney Dysfunctionâ€“Tumour Nephrectomy Database study. <i>Translational Andrology and Urology</i> , 2017, 6, 899-909.	1.4	4
242	Dramatic response of livedoid vasculitis to tissue plasminogen activator (tPA). <i>Australian and New Zealand Journal of Medicine</i> , 1995, 25, 370-371.	0.5	3
243	Probable tacrolimus toxicity from tibolone co-administration in a woman: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 276.	0.8	3
244	Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions. <i>Peritoneal Dialysis International</i> , 2016, 36, 146-153.	2.3	3
245	Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. <i>Nephrology</i> , 2017, 22, 823-824.	1.6	3
246	Representativeness of Honeypot Trial Participants to Australasian PD Patients. <i>Peritoneal Dialysis International</i> , 2017, 37, 516-522.	2.3	3
247	Biochemical Targets. <i>Nephrology</i> , 2006, 11, S198-S229.	1.6	2
248	In Reply to â€“Intramuscular or Intradermal Hepatitis B Vaccine Administration in Hemodialysis Patients?â€™. <i>American Journal of Kidney Diseases</i> , 2009, 54, 982.	1.9	2
249	The impact of fibroblast growth factor-23 on the cardiovascular system in chronic kidney disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 565-568.	2.4	2
250	FP55EFFECTS OF FISH OIL SUPPLEMENTATION AND ASPIRIN USE ON NEED FOR ARTERIOVENOUS FISTULA INTERVENTIONS AND CENTRAL VENOUS CATHETERS IN PATIENTS REQUIRING HAEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i227-i227.	0.7	2
251	Representativeness of the PDOPPS cohort compared to the Australian PD population. <i>Peritoneal Dialysis International</i> , 2022, 42, 403-414.	2.3	2
252	Corrigendum for NEP 1662. <i>Nephrology</i> , 2013, 18, 481-481.	1.6	1

#	ARTICLE	IF	CITATIONS
253	Utility of serum beta-trace protein as a tool for estimating residual kidney function in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2021, 41, 226-235.	2.3	1
254	BODY MASS INDEX AND RENAL TRANSPLANT OUTCOMES. <i>Transplantation</i> , 2003, 76, 1651.	1.0	0
255	Clinical research for nephrologists: a practical series. <i>Nephrology</i> , 2010, 15, 7-7.	1.6	0
256	An unusual case of severe acute tubular necrosis. <i>Nephrology</i> , 2014, 19, 62-63.	1.6	0
257	FP558OUTCOMES OF INTEGRATED HOME DIALYSIS CARE: A MULTI-CENTRE REGISTRY STUDY. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii260-iii260.	0.7	0
258	An update on bone imaging and markers in chronic kidney disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 455-466.	2.4	0
259	Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, e149-50.	2.3	0
260	SuO008STANDARDISED OUTCOMES IN NEPHROLOGY (SONG): ESTABLISHING A CORE VASCULAR ACCESS OUTCOME MEASURE FOR TRIALS IN HAEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i619-i619.	0.7	0
261	FP628A CORE OUTCOME SET FOR TRIALS IN HAEMODIALYSIS ESTABLISHED BY THE STANDARDISED OUTCOMES IN NEPHROLOGY - HAEMODIALYSIS INITIATIVE. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i255-i255.	0.7	0
262	Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD. <i>Kidney International Reports</i> , 2021, 6, 1032-1040.	0.8	0